ahlam1399
03-11-2016, 10:48 PM
Infection worries prompt EU review of Gilead leukemia drug
LONDON (Reuters) - European regulators have started a review into the safety of Gilead Sciences' leukemia drug Zydelig due to concerns over serious adverse events, including deaths.
http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/1/rc.img (http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/2/rc.img (http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/3/rc.img (http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/3/rc.htm)
http://da.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/a2.img (http://da.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/a2.htm)
http://adchoice.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/ach.img (http://adchoice.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/ach.htm)http://pi.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/a2t.imghttp://pi2.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e332ed9/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=vXC3ghKwNps:COMH2VQQtdw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=vXC3ghKwNps:COMH2VQQtdw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=vXC3ghKwNps:COMH2VQQtdw:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=vXC3ghKwNps:COMH2VQQtdw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=vXC3ghKwNps:COMH2VQQtdw:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/vXC3ghKwNps
LONDON (Reuters) - European regulators have started a review into the safety of Gilead Sciences' leukemia drug Zydelig due to concerns over serious adverse events, including deaths.
http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/1/rc.img (http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/1/rc.htm)
http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/2/rc.img (http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/2/rc.htm)
http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/3/rc.img (http://rc.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/rc/3/rc.htm)
http://da.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/a2.img (http://da.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/a2.htm)
http://adchoice.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/ach.img (http://adchoice.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/ach.htm)http://pi.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/a2t.imghttp://pi2.feedsportal.com/r/247394475712/u/49/f/654207/c/35217/s/4e332ed9/sc/13/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e332ed9/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=vXC3ghKwNps:COMH2VQQtdw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=vXC3ghKwNps:COMH2VQQtdw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=vXC3ghKwNps:COMH2VQQtdw:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=vXC3ghKwNps:COMH2VQQtdw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=vXC3ghKwNps:COMH2VQQtdw:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/vXC3ghKwNps